

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fleta Jennifer Solomon
Date of last notice	6 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund - Ms Solomon is a director of the trustee and beneficiary
Date of change	24 April 2023
No. of securities held prior to change	<u>Direct</u> 21,273,439 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 72,000 Share Rights <u>Indirect</u> 250,000 fully paid ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Class	Fully paid ordinary shares
Number acquired	34,000 Fully paid ordinary shares
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration – issued on conversion of vested share rights
No. of securities held after change	<p><u>Direct</u> 21,309,439 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 72,000 Share Rights</p> <p><u>Indirect</u> 250,000 fully paid ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued on conversion of vested share rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael David Lynch-Bell
Date of last notice	6 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	24 April 2023
No. of securities held prior to change	1,383,743 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 140,000 Retention Share Rights
Class	Fully paid ordinary shares
Number acquired	286,248 Fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued in lieu of Director fees as approved by shareholders on 30 August 2022, at a deemed issue price of \$0.237 per share

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	1,669,991 Ordinary shares 250,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 140,000 Retention Share Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares in lieu of Director fees approved at annual meeting on 30 August 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neale William Fong
Date of last notice	6 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Riverpalm Pty Ltd ATF NW Fong Family Trust - Dr Fong is a director and beneficiary of the trust Dr Neale Fong ATF Damblock Trust - Dr Fong is a trustee and beneficiary of the trust
Date of change	24 April 2023
No. of securities held prior to change	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares Dr Neale Fong <Damblock Trust> 1,066,871 Ordinary shares 70,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Class	Fully paid ordinary shares
Number acquired	143,453 Fully paid ordinary shares
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued in lieu of Director fees as approved by shareholders on 30 August 2022, at a deemed issue price of \$0.237 per share
No. of securities held after change	Riverpalm Pty Ltd <NW Fong Family Trust> 296,154 Ordinary shares Dr Neale Fong <Damblock Trust> 1,210,324 Ordinary shares 70,000 Retention Share Rights 125,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares in lieu of Director fees approved at annual meeting on 30 August 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Angus McDougall Caithness
Date of last notice	6 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd - Mr Caithness is a director Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund - Mr Caithness is a director of the trustee and beneficiary
Date of change	24 April 2023

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p><u>Direct</u> 2,010,942 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p> <p><u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 9,016,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 64,000 Share Rights</p> <p><i>Angus Caithness SMSF Pty Ltd <the Caithness Superannuation Fund></i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024</p>
<p>Class</p>	<p>Fully paid ordinary shares</p>
<p>Number acquired</p>	<p>(a) 228,629 Fully paid ordinary shares (b) 32,000 Fully paid ordinary shares</p>
<p>Number disposed</p>	<p>(b) 32,000 Share rights (on conversion)</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>(a) Issued in lieu of Director fees as approved by shareholders on 30 August 2022, at a deemed issue price of \$0.25 (b) Nil consideration – issued on conversion of vested share rights</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<u>Direct</u> 2,239,571 Ordinary shares 100,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024 <u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 9,048,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 32,000 Share Rights <i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 150,000 Ordinary shares 150,000 Unlisted options, exercisable at \$0.25 each, expiring 19 July 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Issue of shares in lieu of Director fees approved at annual meeting on 30 August 2022 (b) Issued on conversion of vested share rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.